睿知中国医院研究地图
候选清单

北京首都医科大学

首都医科大学附属北京朝阳医院

Beijing Chao-Yang Hospital

在本站收录的 53 种疾病中,这家医院列在其中 21 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

官方链接已于 2026-11-08 打开核对。

联系这家医院

首都医科大学附属北京朝阳医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 食管鳞状细胞癌Oesophageal squamous cell carcinoma8 篇牵头论文
  2. 肝细胞癌Hepatocellular carcinoma18 篇牵头论文
  3. 胃癌Stomach cancer12 篇牵头论文
  4. 脊索瘤Chordoma2 篇牵头论文
  5. 骨肉瘤Osteosarcoma6 篇牵头论文
  6. 胃肠道间质瘤Gastrointestinal stromal tumour0 篇牵头论文
  7. 神经母细胞瘤Neuroblastoma1 篇牵头论文
  8. 尤文肉瘤Ewing sarcoma2 篇牵头论文
  9. 多发性骨髓瘤Multiple myeloma52 篇牵头论文
  10. β 地中海贫血Beta thalassaemia0 篇牵头论文
  11. 非典型溶血性尿毒症综合征Atypical haemolytic uraemic syndrome0 篇牵头论文
  12. 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura0 篇牵头论文
  13. 大动脉炎Takayasu arteritis3 篇牵头论文
  14. 特发性肺纤维化Idiopathic pulmonary fibrosis12 篇牵头论文
  15. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis1 篇牵头论文
  16. 白塞病Behçet disease1 篇牵头论文
  17. IgA 肾病IgA nephropathy4 篇牵头论文
  18. 原发性胆汁性胆管炎Primary biliary cholangitis3 篇牵头论文
  19. 原发性硬化性胆管炎Primary sclerosing cholangitis2 篇牵头论文
  20. 先天性膈疝Congenital diaphragmatic hernia1 篇牵头论文
  21. 家族性腺瘤性息肉病Familial adenomatous polyposis0 篇牵头论文

未列出的收录疾病:鼻咽癌、肝母细胞瘤、视网膜母细胞瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、血友病 A、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 8 篇,占 0.3%。

牵头论文
8
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 2220232024: 3320242025: 112025

北京有 13 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录
研究主题免疫治疗分子标志物与基因
论文中的科室病理/检验科肿瘤内科
牵头的论文8
  1. p53 and Ki-67 combined with periodic acid-Schiff staining for the diagnosis of early stage esophageal squamous cell carcinoma lesions in biopsy specimens.2025Esophagus : official journal of the Japan Esophageal Society免费全文
  2. Phospholipase PLCE1 Promotes Transcription and Phosphorylation of MCM7 to Drive Tumor Progression in Esophageal Cancer.2024Cancer research
  3. Expression and correlation of PD-L1 and HER2 in oesophageal squamous cell carcinoma.2024Journal of clinical pathology
  4. Correlation of PD-L1 expression with CD8+ T cells and oxidative stress-related molecules NRF2 and NQO1 in esophageal squamous cell carcinoma.2024The journal of pathology. Clinical research免费全文
  5. Preventive Treatment with PD-1 Antibody Increases Tissue-resident Memory T Cells Infiltration and Delays Esophageal Carcinogenesis.2023Cancer prevention research (Philadelphia, Pa.)免费全文
  6. APOC1 predicts a worse prognosis for esophageal squamous cell carcinoma and is associated with tumor immune infiltration during tumorigenesis.2023Pathology oncology research : POR免费全文
  7. High expression of nuclear NRF2 combined with NFE2L2 alterations predicts poor prognosis in esophageal squamous cell carcinoma patients.2022Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  8. DCLK1-Short Splice Variant Promotes Esophageal Squamous Cell Carcinoma Progression via the MAPK/ERK/MMP2 Pathway.2021Molecular cancer research : MCR
PubMed 以外找到的论文(未计入)12
  1. 193P DCLK1’s kinase activity drives its pro-stemness effect in esophageal squamous cell carcinoma2024Annals of Oncology论文
  2. Data from DCLK1-Short Splice Variant Promotes Esophageal Squamous Cell Carcinoma Progression via the MAPK/ERK/MMP2 Pathway2023未列出期刊其他
  3. Supplementary Figure 4 from DCLK1-Short Splice Variant Promotes Esophageal Squamous Cell Carcinoma Progression via the MAPK/ERK/MMP2 Pathway2023未列出期刊补充材料
  4. Additional file 10 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  5. Additional file 11 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  6. Additional file 12 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  7. Additional file 13 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  8. Additional file 14 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  9. Additional file 15 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  10. Additional file 9 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  11. RETRACTED ARTICLE: Tumor-associated fibroblasts derived exosomes induce the proliferation and cisplatin resistance in esophageal squamous cell carcinoma cells through RIG-I/IFN-β signaling2022Figshare数据集
  12. Efficacy and safety of KN046 plus paclitaxel/cisplatin as first-line treatment for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncology会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 18 篇,占 0.1%。

牵头论文
18
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 5520222023: 5520232024: 4420242025: 112025

北京有 17 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的肝细胞癌开放试验。

这些数字背后的记录
研究主题复发与预后手术与肝移植局部治疗(消融、TACE、HAIC)
论文中的科室普外/肝胆胰外科影像/核医学科
牵头的论文18
  1. Integrated analysis and experimental validation reveal the prognostic and immunological features associated with coagulation in hepatocellular carcinoma.2025Scientific reports免费全文
  2. LAPTM4B-mediated hepatocellular carcinoma stem cell proliferation and MDSC migration: implications for HCC progression and sensitivity to PD-L1 monoclonal antibody therapy.2024Cell death & disease免费全文
  3. Impact of metabolic dysfunction-associated fatty liver disease on liver transplant recipients with hepatitis B virus-related hepatocellular carcinoma.2024European journal of clinical nutrition
  4. Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma.2024Frontiers in endocrinology免费全文
  5. Anti-PD-1 therapy reverses TIGIT+CD226+NK depletion in immunotherapy resistance of hepatocellular carcinoma through PVR/TIGIT pathway.2024International immunopharmacology
  6. Metformin promotes the normalization of abnormal blood vessels after radiofrequency ablation deficiency in hepatocellular carcinoma by microRNA-302b-3p targeting thioredoxin-interacting protein.2023Acta biochimica Polonica
  7. Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies.2023Cancer biology & medicine免费全文
  8. Therapeutically targeting essential metabolites to improve immunometabolism manipulation after liver transplantation for hepatocellular carcinoma.2023Frontiers in immunology免费全文
  9. Preoperative systemic inflammatory response index predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation.2023Frontiers in immunology免费全文
  10. Unveiling the Mystery of SUMO-activating enzyme subunit 1: A Groundbreaking Biomarker in the Early Detection and Advancement of Hepatocellular Carcinoma.2023Transplantation proceedings
  11. Prognosis of Liver Transplantation for Hepatocellular Carcinoma in Terms of Different Criteria: A Single Center Experience.2022Current medical science
  12. Anatomic resection versus radiofrequency ablation with an ablative margin ≥ 1.0 cm for solitary small hepatocellular carcinoma measuring ≤ 3 cm: Comparison of long-term outcomes using propensity score matching analysis.2022European journal of radiology
  13. Safety and efficacy of microwave versus radiofrequency ablation for large hepatic hemangioma: a multicenter retrospective study with propensity score matching.2022European radiology
  14. Arsenic trioxide inhibits angiogenesis of hepatocellular carcinoma after insufficient radiofrequency ablation via blocking paracrine angiopoietin-1 and angiopoietin-2.2022International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  15. Sirolimus increases the anti-cancer effect of Huai Er by regulating hypoxia inducible factor-1α-mediated glycolysis in hepatocellular carcinoma.2022World journal of gastroenterology免费全文
  16. Intrahepatic hemorrhage and recurrence caused by arterioportal fistula after radiofrequency ablation for hepatocellular carcinoma: A thought-provoking ablation-related complication.2021Asian journal of surgery
  17. The ratio of preoperative alpha-fetoprotein level to total tumor volume as a prognostic factor of hepatocellular carcinoma after liver transplantation.2021Medicine免费全文
  18. PD-L1+NEUT, Foxp3+Treg, and NLR as New Prognostic Marker with Low Survival Benefits Value in Hepatocellular Carcinoma.2021Technology in cancer research & treatment免费全文
中文论文(未计入)1
  1. [Angio-associated migratory cell protein is highly expressed in hepatocellular carcinoma and promotes tumor cell invasion and metastasis].2025Nan fang yi ke da xue xue bao = Journal of Southern Medical University免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Liver Transplantation With ADV-TK Gene Therapy Improves Survival in Patients With Advanced Hepatocellular Carcinoma已完成NCT00300521牵头方II期2000-09 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 12 篇,占 0.1%。

牵头论文
12
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 2220222023: 1120232024: 4420242025: 222025

北京有 15 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    分期
    未注明
    开始
    2025-02
    登记号
    NCT06846996

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、台州、天津、太原、广州、徐州、杭州、汕头、沈阳、海口、福州、郑州、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题营养与康复腹膜转移与晚期影像与人工智能
论文中的科室病理/检验科消化/肝病科普外/肝胆胰外科影像/核医学科
牵头的论文12
  1. Lipidomic machine learning predictor for progression of gastric cancer.2026Clinica chimica acta; international journal of clinical chemistry
  2. Clinicopathological features and mucin expression of early papillary gastric adenocarcinoma.2025Scientific reports免费全文
  3. Diagnostic Value of Joint Detection of Serum TK1, TSGF, CA199, and CA724 for Gastric Cancer and Its Relationship With Clinicopathologic Features and Prognosis.2025The American surgeon
  4. GGT5: a potential immunotherapy response inhibitor in gastric cancer by modulating GSH metabolism and sustaining memory CD8+ T cell infiltration.2024Cancer immunology, immunotherapy : CII免费全文
  5. Gastric Cancer Immune Subtypes and Prognostic Modeling: Insights from Aging-Related Gene Analysis.2024Critical reviews in immunology
  6. Advanced Gastric Cancer: CT Radiomics Prediction of Lymph Modes Metastasis After Neoadjuvant Chemotherapy.2024Journal of imaging informatics in medicine免费全文
  7. DNA methylation profiling identifies epigenetic signatures of early gastric cancer.2024Virchows Archiv : an international journal of pathology
  8. Multimodality Therapy, Followed by Laparoscopic Gastrectomy, for Unresectable Gastric Cancer With Outlet Obstruction and Bulky N2 Metastases.2023Surgical laparoscopy, endoscopy & percutaneous techniques
  9. Clinicopathological and molecular characteristics of the alpha-fetoprotein-producing gastric cancer: emphasis on two major subtypes.2022APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  10. Deep learning for automatic diagnosis of gastric dysplasia using whole-slide histopathology images in endoscopic specimens.2022Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  11. Silencing of ER-resident oxidoreductase PDIA3 inhibits malignant biological behaviors of multidrug-resistant gastric cancer.2021Acta biochimica et biophysica Sinica
  12. Efficacy of apatinib combined with tegafur gimeracil and oteracil potassium in the second-line treatment of advanced gastric cancer.2021Journal of B.U.ON. : official journal of the Balkan Union of Oncology
中文论文(未计入)6
  1. [Neuroendocrine carcinoma with significantly vacuolar nucleus at the esophagogastric junction: A case report].2025Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences免费全文
  2. [Clinicopathological features of Helicobacter pylori-negative early gastric cancer].2023Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences免费全文
  3. [The value of Alcian blue periodic acid Schiff staining and Ki-67 expression in diagnosing gastric reactive epithelial hyperplasia and dysplasia].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
  4. [Clinicopathological features of early gastric cancer after Helicobacter pylori eradication].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
  5. [Clinicopathological features of very well-differentiated adenocarcinoma of the stomach].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
  6. [Application and Progress of Convolutional Neural Network-based Pathological Diagnosis of Gastric Cancer].2021Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
  1. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China正在招募NCT06846996研究中心2025-02 启动
  2. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers进行中,不再招募NCT05152147研究中心III期2021-12 启动
  3. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  4. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer状态不明NCT04486651研究中心III期2020-09 启动
  5. Incidence of Pancreatic Fistula After Radical Gastrectomy状态不明NCT03391687研究中心2017-12 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

脊索瘤

Chordoma

2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.9%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

北京有 11 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.3%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 2220242025: 112025

北京有 48 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室肿瘤内科病理/检验科影像/核医学科

这些论文过半是实验室或动物研究。

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年没有牵头胃肠道间质瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 23 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

北京有 24 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室神经外科

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

北京有 17 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录
论文中的科室病理/检验科影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 52 篇,占 3.1%。

牵头论文
52
2021–2025 年
牵头试验
4
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
14
由其他机构牵头
每年牵头的论文数
2021: 111120212022: 7720222023: 9920232024: 171720242025: 772025

北京有 15 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 14

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    分期
    I期
    开始
    2026-05
    登记号
    NCT07477587

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛

  2. 正在招募
    A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-05
    登记号
    NCT07518186

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心北京、南京、南昌、天津、成都、杭州、武汉、深圳、温州、西安、长春

  3. 正在招募
    Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
    分期
    I期
    开始
    2026-03
    登记号
    NCT07529782

    年龄 未注明 至 18 岁(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心北京、天津、杭州、济南、苏州

  4. 正在招募
    Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA
    分期
    I期
    开始
    2026-09
    登记号
    NCT07620275

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:中国人民解放军总医院;另有 2 家列出的医院为研究中心北京、天津

  5. 正在招募
    A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
    分期
    III期
    开始
    2025-12
    登记号
    NCT07297329

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京

  6. 正在招募
    Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    I期
    开始
    2024-05
    登记号
    NCT06375044

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心北京、南京、天津、广州、杭州、福州、郑州

  7. 正在招募
    A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
    分期
    III期
    开始
    2024-06
    登记号
    NCT06508983

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心北京、天津、广州、杭州、武汉、苏州、西安、郑州

  8. 正在招募
    A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    I期
    开始
    2024-06
    登记号
    NCT06574568

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心北京、哈尔滨、太原、广州、杭州、济南、郑州

  9. 正在招募
    Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
    分期
    I/II期
    开始
    2023-02
    登记号
    NCT05565807

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心北京、杭州

  10. 正在招募
    Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
    分期
    III期
    开始
    2022-09
    登记号
    NCT05243797

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、天津、杭州、武汉、沈阳、济南、温州、郑州、长春

  11. 正在招募
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    分期
    III期
    开始
    2022-10
    登记号
    NCT05552222

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南京、南宁、南昌、厦门、哈尔滨、天津、常州、广州、成都、杭州、武汉、沈阳、济南、深圳、温州、福州、西安、郑州、重庆、长春、长沙

  12. 正在招募
    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
    分期
    I/II期
    开始
    2021-09
    登记号
    NCT04973605

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南京、南昌、厦门、天津、杭州、武汉、沈阳、石家庄、福州、郑州、重庆、长沙、青岛

  13. 即将招募
    Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
    分期
    II期
    开始
    2027-12
    登记号
    NCT07695740

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心北京

  14. 即将招募
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-06
    登记号
    NCT07569757

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 38 家列出的医院为研究中心上海、兰州、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、徐州、成都、承德、昆明、杭州、株洲、沈阳、泸州、济南、湛江、石家庄、蚌埠、西安、贵阳、郑州、重庆、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层联合用药干细胞移植
论文中的科室病理/检验科影像/核医学科肿瘤内科
牵头的论文52
  1. Prognostic Implications of Measurable Residual Disease and Autologous Hematopoietic Stem Cell Transplantation in Primary Plasma Cell Leukemia in the Era of Novel Agents.2026Transplantation and cellular therapy
  2. The prognostic impact of 1q21 gain/amplification in newly diagnosed multiple myeloma: a retrospective study based on a single center in China.2025Annals of hematology
  3. Temporal trends and disparities in cardiovascular disease-related mortality among adults with multiple myeloma in the United States, 1999-2023.2025BMC cardiovascular disorders免费全文
  4. Prognostic value of the expression of CD27 and CD117 in newly diagnosed multiple myeloma patients.2025BMC immunology免费全文
  5. Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi-Center, Open-Label Phase I Trial.2025Cancer medicine免费全文
  6. Pretreatment hemoglobin, myeloma subtype, and induction regimens as independent prognostic factors for survival after autologous stem cell transplantation in multiple myeloma: a retrospective cohort study.2025Hematology (Amsterdam, Netherlands)
  7. Exploring multiple myeloma pathobiology and immune cell signatures: Evidence from bidirectional genetic analysis.2025Medicine免费全文
  8. Analysis of clinical characteristics, treatment response, and prognosis among 67 patients with anaplastic multiple myeloma.2025World journal of surgical oncology免费全文
  9. Development of a clinical prognostic model for primary plasma cell leukemia patients treated with novel agents: a multicenter retrospective cohort study.2024Annals of hematology
  10. Prognostic value of 18F-FDG PET/CT in patients with relapsed multiple myeloma.2024Annals of hematology
  11. Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial.2024Annals of hematology免费全文
  12. Myeloma extracellular vesicle-derived RAGE increases inflammatory responses and myotube atrophy in multiple myeloma through activation of the TLR4/NF-κB p65 pathway.2024Apoptosis : an international journal on programmed cell death
  13. Evaluation of the Prognostic Value of the Mayo Additive Staging System and Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients.2024Cancer medicine免费全文
  14. Assessment of prolonged proteasome inhibition through ixazomib-based oral regimen on newly diagnosed and first-relapsed multiple myeloma: A real-world Chinese cohort study.2024Cancer medicine免费全文
  15. KIAA1429 increases FOXM1 expression through YTHDF1-mediated m6A modification to promote aerobic glycolysis and tumorigenesis in multiple myeloma.2024Cell biology and toxicology免费全文
  16. Detection of lenalidomide metabolites in urine to discover drug-resistant compounds.2024Clinica chimica acta; international journal of clinical chemistry
  17. Proteomics analysis of serum and urine identifies VCP and CTSA as potential biomarkers associated with multiple myeloma.2024Clinica chimica acta; international journal of clinical chemistry
  18. Bone marrow fibrosis in newly diagnosed multiple myeloma and its correlation with clinicopathological factors.2024Diagnostic pathology免费全文
  19. Analysis of the efficacy of separation surgery for severe neurological compression in multiple myeloma: a retrospective analysis of 35 cases.2024European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  20. Case report: Dual-targeted BCMA and CS1 CAR-T-cell immunotherapy in recurrent and refractory extramedullary multiple myeloma.2024Frontiers in immunology免费全文
  21. Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal plasmacytomas: a retrospective study in a single center.2024Hematology (Amsterdam, Netherlands)
  22. Synchronous multiple myeloma and lung adenocarcinoma: A clinical series.2024Indian journal of pathology & microbiology
  23. Chromosome 1q21 Aberrations Are Poor Prognostic Factors for Newly Diagnosed Multiple Myeloma Patients.2024Journal of clinical laboratory analysis免费全文
  24. Wound healing after surgical therapy for multiple myeloma: a case-control study.2024Journal of wound care
  25. Which factors are associated with adverse prognosis in multiple myeloma patients after surgery? - preliminary establishment and validation of the nomogram.2024World journal of surgical oncology免费全文
  26. The MODIFY Study Protocol: An Open-Label, Single-Arm, Multicenter, Prospective Pragmatic Study of Ixazomib-Based Triple-Drug Therapy in Chinese Patients with Multiple Myeloma.2023Advances in therapy免费全文
  27. Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial.2023BMC cancerRCT免费全文
  28. Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment.2023Blood advances免费全文
  29. Prognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era.2023Cancer medicine免费全文
  30. Low Barthel index score is a poor prognostic factor for newly diagnosed multiple myeloma patients.2023Clinical and experimental medicine
  31. In vivo antitumor efficacy of 17-AAG loaded PMMA in a human multiple myeloma xenograft mouse model.2023Clinical and experimental medicine
  32. Prognostic value of t(4;14) translocation in newly diagnosed multiple myeloma patients in novel agent era.2023Hematology (Amsterdam, Netherlands)
  33. Biological research on the occurrence and development of multiple myeloma and its treatment.2023Immunity, inflammation and disease免费全文
  34. The effects of nutritional support on cellular immunity of the patient with multiple myeloma undergoing chemotherapy.2023Panminerva medica
  35. Triplet RVd Induction for Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis.2022Advances in therapy
  36. Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation.2022BMC cancer免费全文
  37. Incidence of multiple myeloma in Kailuan cohort: A prospective community-based study in China.2022Cancer epidemiology
  38. Echocardiography-defined pulmonary hypertension is an adverse prognostic factor for newly diagnosed multiple myeloma patients.2022Cancer medicine免费全文
  39. Ixazomib-based maintenance therapy after bortezomib-based induction in patients with multiple myeloma not undergoing transplantation: A real-world study.2022Cancer medicine免费全文
  40. Routine blood biomarkers for the detection of multiple myeloma using machine learning.2022International journal of laboratory hematology
  41. The Association Between Low T3 Syndrome and Survival in Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study.2022Technology in cancer research & treatment免费全文
  42. Pleural effusion-based nomogram to predict outcomes in unselected patients with multiple myeloma: a large single center experience.2021Annals of hematology
  43. The Prognostic Role of Prothrombin Time and Activated Partial Thromboplastin Time in Patients with Newly Diagnosed Multiple Myeloma.2021BioMed research international免费全文
  44. Autologous peripheral blood stem cell transplantation as front-line therapy for myeloma with double-hit and triple-hit in a real-world study.2021Chinese medical journal免费全文
  45. Promoting effects of MiR-135b on human multiple myeloma cells via regulation of the Wnt/β-catenin/Versican signaling pathway.2021Cytokine
  46. The Prevalence of Euthyroid Hypertriiodothyroninemia in Newly Diagnosed Multiple Myeloma and its Clinical Characteristics.2021Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  47. A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China.2021International journal of hematology
  48. Deep Learning-Based CT Imaging in Diagnosing Myeloma and Its Prognosis Evaluation.2021Journal of healthcare engineering免费全文
  49. At least two high-risk cytogenetic abnormalities indicate the inferior outcomes for newly diagnosed multiple myeloma patients: a real-world study in China.2021Leukemia & lymphoma
  50. Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients.2021Leukemia & lymphoma
  51. LncRNA ANRIL promotes multiple myeloma progression and bortezomib resistance by EZH2-mediated epigenetically silencing of PTEN.2021Neoplasma
  52. Clinical Significance of TP53 Abnormalities in Newly Diagnosed Multiple Myeloma.2021Turkish journal of haematology : official journal of Turkish Society of Haematology免费全文
中文论文(未计入)20
  1. [The Influence of COVID-19 Infection on the Mobilization and Collection of Autologous Peripheral Blood Stem Cells in Patients with Multiple Myeloma].2025Zhongguo shi yan xue ye xue za zhi
  2. [Clinical Analysis of Listeriosis in Treatment of Multiple Myeloma with Novel Agents].2025Zhongguo shi yan xue ye xue za zhi
  3. [Analysis of the efficacy of a carfilzomib-based regimen in the treatment of relapsed and refractory multiple myeloma].2025Zhonghua nei ke za zhi
  4. [Advances for treatment of relapsed or refractory multiple myeloma: interpretation of guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)].2024Zhonghua nei ke za zhi
  5. [Prognostic value of the Second Revision of the International Staging System in patients with newly diagnosed transplant-eligible multiple myeloma].2024Zhonghua nei ke za zhi
  6. [Prognostic analysis of 19 newly treated multiple myeloma patients with t(14; 16)].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  7. [Analysis of the prognostic factors in primary plasma cell leukemia in the era of novel agents].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  8. [Comparison of etoposide combined with G-CSF and cyclophosphamide combined with G-CSF in the mobilization of autologous peripheral blood stem cells in patients with multiple myeloma].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  9. [Minimal residual disease assessment and progress in multiple myeloma].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  10. [MiR-203a-5p Inhibits Multiple Myeloma Cell Proliferation and Cell Cycle Progression via Targeting JAG1].2023Zhongguo shi yan xue ye xue za zhi
  11. [Application and significance of peripheral blood circulating plasma cells in the diagnosis of multiple myeloma].2023Zhonghua bing li xue za zhi = Chinese journal of pathology
  12. [Prognostic significance of immunoparesis in newly diagnosed multiple myeloma patients who achieved deep response].2022Zhonghua nei ke za zhi
  13. [Interpretation of treatment of relapsed/refractory multiple myeloma patients in the guidelines for the diagnosis and management of multiple myeloma in China(2022 revision)].2022Zhonghua nei ke za zhi
  14. [The prognostic relationship between CD56 expression and newly diagnosed multiple myeloma].2022Zhonghua nei ke za zhi
  15. [Clinical analysis of 25 patients with non transplanted multiple myeloma who survived for more than 10 years].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  16. [MAS-like lesions and SIADH caused by bortezomib in the treatment of multiple myeloma : three cases report and literature review].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  17. [The prognostic value of dynamic minimal residual disease after autologous hematopoietic stem cell transplantation in patients with multiple myeloma in novel-agent era].2022Zhonghua yi xue za zhi
  18. [Controversies on the diagnosis and treatment of relapsed/refractory multiple myeloma].2022Zhonghua yi xue za zhi
  19. [Clinical Analysis of 25 Non-Transplanted Multiple Myeloma Patients Treated with Bortezomib Maintenance].2021Zhongguo shi yan xue ye xue za zhi
  20. [Autologous stem cell transplantation improve the survival of newly diagnosed multiple myeloma patients].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)45
  1. Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omics状态不明NCT04678089牵头方2019-05 启动
  2. CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma状态不明NCT02336386牵头方III期2014-12 启动
  3. Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma Patients状态不明NCT02981199牵头方(推断)不分期2016-01 启动
  4. Comparing Intermediate-dose CTX+ G-CSF Plus or Not rhTPO for PB CD34+ Cells Mobilization in MM Patients状态不明NCT02572596牵头方(推断)不分期2013-01 启动
  5. Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma即将招募NCT07695740研究中心II期2027-12 启动
  6. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma正在招募NCT07518186研究中心III期2026-05 启动
  7. Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma正在招募NCT07529782研究中心I期2026-03 启动
  8. Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA正在招募NCT07620275研究中心I期2026-09 启动
  9. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma即将招募NCT07569757研究中心III期2026-06 启动
  10. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma正在招募NCT07477587研究中心I期2026-05 启动
  11. A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant正在招募NCT07297329研究中心III期2025-12 启动
  12. Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma正在招募NCT06375044研究中心I期2024-05 启动
  13. A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients正在招募NCT06508983研究中心III期2024-06 启动
  14. A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma正在招募NCT06574568研究中心I期2024-06 启动
  15. Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma正在招募NCT05565807研究中心I/II期2023-02 启动
  16. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation正在招募NCT05243797研究中心III期2022-09 启动
  17. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma正在招募NCT05552222研究中心III期2022-10 启动
  18. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma正在招募NCT04973605研究中心I/II期2021-09 启动
  19. A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT07266441研究中心II期2026-02 启动
  20. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide进行中,不再招募NCT06208150研究中心III期2024-01 启动
  21. Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT06158841研究中心III期2024-05 启动
  22. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)进行中,不再招募NCT06464991研究中心III期2024-03 启动
  23. A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT05572515研究中心III期2023-03 启动
  24. A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment进行中,不再招募NCT05455320研究中心III期2022-10 启动
  25. A Study of Daratumumab进行中,不再招募NCT05438043研究中心III期2022-12 启动
  26. A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma状态不明NCT05236621研究中心III期2021-01 启动
  27. SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies进行中,不再招募NCT04684108研究中心I期2021-11 启动
  28. A Study of NINLARO® in Chinese Adults With Multiple Myeloma进行中,不再招募NCT05013190研究中心2021-10 启动
  29. A Study of TQB3820 in Patients With Hematological Malignancies状态不明NCT05020639研究中心I期2021-08 启动
  30. Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma状态不明NCT04818372研究中心I期2021-04 启动
  31. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)已完成NCT04939142研究中心III期2021-07 启动
  32. APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma状态不明NCT04674514研究中心I/II期2021-04 启动
  33. Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM状态不明NCT05052970研究中心I期2021-10 启动
  34. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT05083169研究中心III期2021-10 启动
  35. A Study of Ninlaro in Real World Clinical Practice in China已完成NCT04328662研究中心2020-05 启动
  36. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)状态不明NCT03975907研究中心I/II期2019-06 启动
  37. Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)已完成NCT03748953研究中心III期2019-01 启动
  38. TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma已完成NCT03860038研究中心II期2019-01 启动
  39. A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma已完成NCT03944057研究中心II期2019-09 启动
  40. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma已完成NCT03952091研究中心III期2019-03 启动
  41. A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.进行中,不再招募NCT03539744研究中心III期2018-10 启动
  42. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)已完成NCT03217812研究中心III期2017-11 启动
  43. Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma已完成NCT03029234研究中心III期2017-03 启动
  44. A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)已完成NCT02312258研究中心III期2015-04 启动
  45. Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma已完成NCT01818752研究中心III期2013-07 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

β 地中海贫血

Beta thalassaemia

2021–2025 年没有牵头β 地中海贫血的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 10 家医院列在β 地中海贫血下全国有 157 家医院列在β 地中海贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的β 地中海贫血开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Detection of three common mutations causing β-thalassemia by using a closed-tube multiplex PCR.2018Experimental and molecular pathology

打开 PubMed 检索ClinicalTrials.gov

血液疾病

非典型溶血性尿毒症综合征

Atypical haemolytic uraemic syndrome

2021–2025 年没有牵头非典型溶血性尿毒症综合征的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 6 家医院列在非典型溶血性尿毒症综合征下全国有 31 家医院列在非典型溶血性尿毒症综合征下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的非典型溶血性尿毒症综合征开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血栓性血小板减少性紫癜

Thrombotic thrombocytopenic purpura

2021–2025 年没有牵头血栓性血小板减少性紫癜的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 8 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.6%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 2220232024: 0020242025: 002025

北京有 30 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录
论文中的科室影像/核医学科风湿免疫科
牵头的论文3
  1. Predictors for pulmonary artery involvement in Takayasu arteritis and its cluster analysis.2023Arthritis research & therapy
  2. Analysis of clinical features between active and inactive patients of Takayasu's arteritis with pulmonary arteries involvement.2023International journal of cardiology
  3. Value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the evaluation of pulmonary artery activity in patients with Takayasu's arteritis.2021European heart journal. Cardiovascular Imaging
中文论文(未计入)1
  1. [Takayasu arteritis with pulmonary artery involvement initially presenting as community-acquired pneumonia].2023Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
早期论文(2016–2020 年)3
  1. Clinical and imaging manifestations of Takayasu's arteritis with pulmonary hypertension: A retrospective cohort study in China.2019International journal of cardiology
  2. [Pulmonary cavities with Takayasu arteritis: report of 3 cases and literature review].2018Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  3. [The analysis of the clinical records diagnosed as Takayasu's arteritis with pulmonary vascular involvement].2016Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis已完成NCT03096275研究中心III期2017-03 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 12 篇,占 1.2%。

牵头论文
12
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 7720232024: 2220242025: 112025

北京有 27 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    分期
    III期
    开始
    2026-09
    登记号
    NCT07687459

    年龄 40 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 45 家列出的医院为研究中心Yuncheng、上海、乌鲁木齐、北京、南京、南宁、南昌、南阳、厦门、合肥、呼和浩特、天津、太原、宁波、宜昌、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、石家庄、福州、西安、郑州、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室风湿免疫科
牵头的论文12
  1. Immunological Features and Potential Biomarkers of Systemic Sclerosis-Associated Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis.2025The clinical respiratory journal
  2. Identifying prothrombin and bone sialoprotein as potential drug targets for idiopathic pulmonary fibrosis.2024BMC pulmonary medicine
  3. Clinical manifestations and prognostic factors analysis of patients hospitalised with acute exacerbation of idiopathic pulmonary fibrosis and other interstitial lung diseases.2024BMJ open respiratory research
  4. Mendelian randomization analysis suggests no causal influence of gastroesophageal reflux disease on the susceptibility and prognosis of idiopathic pulmonary fibrosis.2023BMC pulmonary medicine
  5. Cluster features in fibrosing interstitial lung disease and associations with prognosis.2023BMC pulmonary medicine
  6. Serum Rcn3 level is a potential diagnostic biomarker for connective tissue disease-associated interstitial lung disease and reflects the severity of pulmonary function.2023BMC pulmonary medicine
  7. MMP19 Variants in Familial and Sporadic Idiopathic Pulmonary Fibrosis.2023Lung
  8. Characteristics of Chest HRCT and pulmonary function tests in elderly-onset primary Sjögren syndrome with interstitial lung disease.2023Medicine
  9. TGFβ1-RCN3-TGFBR1 loop facilitates pulmonary fibrosis by orchestrating fibroblast activation.2023Respiratory research
  10. Newly diagnosed non-small cell lung cancer with interstitial lung abnormality: Prevalence, characteristics, and prognosis.2023Thoracic cancer
  11. Air pollution and hospitalization of patients with idiopathic pulmonary fibrosis in Beijing: a time-series study.2022Respiratory research
  12. Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China.2021BMC pulmonary medicine
中文论文(未计入)1
  1. [Research progress of occupational and environmental exposure and idiopathic pulmonary fibrosis].2022Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases
早期论文(2016–2020 年)21
  1. Identification of common signatures in idiopathic pulmonary fibrosis and lung cancer using gene expression modeling.2020BMC cancer
  2. HYAL1 Is Downregulated in Idiopathic Pulmonary Fibrosis and Inhibits HFL-1 Fibroblast Proliferation When Upregulated.2020BioMed research international
  3. Evaluation of health-related quality of life and the related factors in a group of Chinese patients with interstitial lung diseases.2020PloS one
  4. Mechanical ventilation for acute respiratory failure due to idiopathic pulmonary fibrosis versus connective tissue disease-associated interstitial lung disease: Effectiveness and risk factors for death.2020The clinical respiratory journal
  5. [Postinflammatroy pulmonary fibrosis of COVID-19: the current status and perspective].2020Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  6. [A concise review of telomere and telomerase-related genetic markers in fibrotic lung diseases].2020Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases
  7. Independent Clinical Factors Relevant to Prognosis of Patients with Idiopathic Pulmonary Fibrosis.2019Medical science monitor : international medical journal of experimental and clinical research
  8. Clinical features and prognosis of microscopic polyangiitis with usual interstitial pneumonia compared with idiopathic pulmonary fibrosis.2019The clinical respiratory journal
  9. Prognosis of combined pulmonary fibrosis and emphysema: comparison with idiopathic pulmonary fibrosis alone.2019Therapeutic advances in respiratory disease
  10. A Rare Missense Variant in Telomerase Reverse Transcriptase is Associated with Idiopathic Pulmonary Fibrosis in a Chinese Han Family.2018Chinese medical journal
  11. Clinical characteristics of autoimmune rheumatic disease-related organizing pneumonia.2018Clinical rheumatology
  12. Differentiating Usual Interstitial Pneumonia From Nonspecific Interstitial Pneumonia Using High-resolution Computed Tomography: The "Straight-edge Sign".2018Journal of thoracic imaging
  13. Incidence and radiologic-pathological features of lung cancer in idiopathic pulmonary fibrosis.2018The clinical respiratory journal
  14. Risk factors for acute exacerbation of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.2018The clinical respiratory journal
  15. [Real-life experience with pirfenidone in idiopathic pulmonary fibrosis].2018Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  16. Increased activated regulatory T cells proportion correlate with the severity of idiopathic pulmonary fibrosis.2017Respiratory research
  17. Fibrinolytic system related to pulmonary arterial pressure and lung function of patients with idiopathic pulmonary fibrosis.2017The clinical respiratory journal
  18. [Clinical features of acute diffuse pulmonary exudative disorders].2017Zhonghua yi xue za zhi
  19. [Differentially expressed genes analysis in expression profile data of pulmonary fibrosis with pulmonary hypertension].2017Zhonghua yi xue za zhi
  20. Phosphatase and tensin homolog deleted on chromosome 10 contributes to phenotype transformation of fibroblasts in idiopathic pulmonary fibrosis via multiple pathways.2016Experimental biology and medicine (Maywood, N.J.)
  21. miR-130b-3p Modulates Epithelial-Mesenchymal Crosstalk in Lung Fibrosis by Targeting IGF-1.2016PloS one
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)正在招募NCT07687459研究中心III期2026-09 启动
  2. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis即将招募NCT07131150研究中心II期2025-08 启动
  3. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast进行中,不再招募NCT06238622研究中心III期2024-09 启动
  4. A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)已完成NCT06335303研究中心II期2024-09 启动
  5. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis已终止NCT04552899研究中心III期2021-03 启动
  6. Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)已终止NCT04419558研究中心III期2020-09 启动
  7. Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)已终止NCT03955146研究中心III期2019-06 启动
  8. Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)已完成NCT01170065研究中心II期2010-06 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

北京有 19 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
论文中的科室消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

北京有 24 家医院列在白塞病下全国有 149 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.5%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 1120232024: 1120242025: 112025

北京有 32 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
论文中的科室肾内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.0%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 112025

北京有 16 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 2.0%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

北京有 10 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性膈疝

Congenital diaphragmatic hernia

2021–2025 年中国大陆作者发表的 60 篇先天性膈疝 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

北京有 4 家医院列在先天性膈疝下全国有 46 家医院列在先天性膈疝下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性膈疝开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年没有牵头家族性腺瘤性息肉病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 7 家医院列在家族性腺瘤性息肉病下全国有 76 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科
中文论文(未计入)1
  1. [Current management status of hereditary colorectal cancer].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery

打开 PubMed 检索ClinicalTrials.gov

其他相关研究

联系这家医院

出示给工作人员或司机的院名卡

首都医科大学附属北京朝阳医院

Beijing Chao-Yang Hospital

北京

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请以上方链接的医院官方页面为准。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Beijing Chaoyang Hospital; Beijing Chao-yang Hospital; Beijing Chaoyang Hospital Affiliated to Capital Medical University; Myeloma Research Center of Beijing Beijing Chao-Yang Hospital; Beijing Chao-yang Hospital Affiliated with Capital Medical University; Beijing Chao-yang Hospital Affiliated to Capital Medical University; Beijing Chaoyang Hospital Capital Medical University; Capital Medical University Beijing Chaoyang Hospital

提出更正下载数据